English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Coming Home From an Ayahuasca Retreat: What Nobody Warns You About
The plane lands. You collect your bag. Someone at arrivals asks how the trip was, and you open your mouth and realize you have absolutely no idea what to say. That's usually when it hits — the real work of an ayahuasca retreat doesn't end in the maloca. It starts the morning you get home. I've sat in ceremony more times than I can neatly count, and I've spent years helping readers weigh whether plant medicine is right for them. The single most under-discussed part of the whole experience isn't the brew, the purge, or even the visions. It's the re-entry. So let's talk honestly about what happens after an ayahuasca retreat, why the integration window matters so much, and how to protect the shift you traveled so far to find. Most people describe the days right after coming home as tender. Sounds are louder. Small talk feels absurd. The fridge seems full of food you no longer want. You may feel wide open — like the boundary between you and the world got sanded down a couple of layers. That's not your imagination. Ayahuasca appears to increase neuroplasticity for a stretch of days or weeks after ceremony, which is exactly why the after-period is so critical for anyone using plant medicine to work on depression, trauma, or addiction. There's also the plain fact that you probably didn't sleep well at the retreat, didn't eat what you normally eat, and just had a series of experiences your nervous system is still filing away. Expect emotional weather. Tears in the grocery aisle. A sudden clarity about a job you need to leave. A wave of grief you thought you'd already processed a decade ago. None of this means something went wrong — it usually means the medicine is still working. The trap is assuming this openness will last forever. It won't. What you build in the first four to eight weeks tends to be what actually sticks. Integration is one of those words the psychedelic scene throws around a lot without defining. Here's the plain version: integration is the ordinary, unglamorous practice of translating what you saw or felt in ceremony into how you live on a Tuesday. Practically, that means small things repeated. Writing down what you remember before it fades. Sitting quietly for twenty minutes instead of reaching for your phone. Actually calling the person the medicine told you to call. Following through on the promise you made to yourself at 3 a.m. under the mosquito net. A few concrete practices that tend to help: None of this is glamorous. That's why so many people skip it and wonder six months later why the breakthrough faded. A lot of people come home floating. Everything is beautiful. They quit their job, break up with their partner, buy a plane ticket to Peru for next spring, tell everyone at brunch about the vine. This is the ayahuasca honeymoon, and it's real. It's also often followed by a crash three or four weeks later when ordinary life reasserts itself and the felt sense of connection dims. Here's the honest advice: don't make giant, irreversible life decisions in the first month. Not because your insights are wrong — many of them are probably correct — but because the version of you making the decision is still partly in ceremony space. Sit with it. Write it down. Revisit it at week six. If it still feels true, then move. The crash isn't a failure either. It's often the moment the real integration begins, because that's when you have to choose whether to actually change your patterns without the medicine's afterglow doing the lifting for you. Addiction work in particular tends to get tested here. The craving comes back. The old story shows up. What you do in that moment is what determines whether the retreat mattered. This one blindsides almost everyone. You come back with something enormous to share and discover that most people in your life don't have the framework to receive it. Parents worry. Partners feel jealous or confused. Friends nod politely and change the subject. Coworkers definitely do not need to know you spent three nights vomiting in a jungle. A few things I've learned to suggest: The loneliness of coming back is real. Peer integration groups, either online or in person, exist for exactly this reason. Being around other people who've sat with the medicine takes the pressure off your regular relationships to understand something they can't quite reach. Sometimes what comes up after ceremony isn't inspiration. It's fear, panic, intrusive memories, dissociation, or a low mood that won't lift. This is more common than the retreat brochures suggest, particularly for people who came to the medicine with unresolved trauma, which is a lot of us. If you're in that territory, don't tough it out alone. A therapist trained in psychedelic integration — ideally one who understands somatic work — can be the difference between a hard month and a spiral. Grounding practices help too: cold water on the face, weighted blankets, feet on the floor, naming five things you can see. Boring, unsexy, effective. And be careful about jumping back into another ceremony too soon. There's a temptation to think one more sit will resolve what's still churning. Sometimes it does. Often it just piles more material onto a system that hasn't finished digesting the last round. Most experienced facilitators suggest at least three to six months between deep journeys, and honestly, longer is usually better. Some people find one retreat is enough — a single reset that reshapes the years that follow. Others find themselves drawn back, wanting to work with a specific master plant tradition, or curious about other medicines like psilocybin, San Pedro, or ibogaine for addiction recovery. There's no correct answer. What matters is that the next choice comes from clarity, not from chasing a feeling. When you're ready to think about a next retreat, pay attention to the same things that mattered the first time: the lineage and training of the facilitators, the medical screening process, the ratio of participants to helpers, the integration support offered afterward, and whether the container feels honest or performative. If a place promises miracles or rushes you through paperwork, walk away. If something here has left you curious about what your own next step might look like, a range of vetted ayahuasca and plant-medicine retreats can be browsed on our marketplace here. The retreat is the doorway. What you build on the other side is the actual medicine. Take your time with it.
Vitamin D and IBD: How a Simple Nutrient May Calm Gut Inflammation
If you live with inflammatory bowel disease, you already know the strange cruelty of the condition: the body's own defense system, the thing that's supposed to keep you safe, decides your gut is the enemy. Cue the inflammation, the flares that arrive without warning, the exhausting calculus of what you can eat and where the nearest bathroom is. It's a lot. And for years, treatment has largely meant chasing the symptoms with medication rather than addressing the underlying imbalance. So it's worth paying attention when a fresh study points to something as ordinary as vitamin D — the same nutrient your dermatologist nags you about — as a potential ally. Research recently published in Frontiers in Immunology suggests that eight weeks of supplementation can meaningfully shift the immune response inside the gut, quiet inflammatory cells, and even nudge the microbiome toward a healthier composition. That's not a cure. But it's interesting. Inflammatory bowel disease is the umbrella label covering two chronic conditions — ulcerative colitis, which stays confined to the colon, and Crohn's disease, which can show up anywhere along the digestive tract. Both share a common engine: an immune system that's misreading its own tissue as a threat and attacking accordingly. At the cellular level, the trouble comes down to a lopsided fight between two teams of immune cells. Th17 cells are the aggressors. They drive inflammation, ramp up immune activity, and generally push the panic button. Regulatory T cells (Tregs) are the diplomats. Their job is to keep the peace and stop the immune response from spiraling. In a healthy gut, these two are roughly in balance. In IBD, Th17 cells overwhelm the Tregs, and the inflammation just keeps rolling. Now layer in the microbiome. The trillions of bacteria in your gut aren't just passive tenants — they're in constant dialogue with your immune system, sending chemical signals that either dial inflammation up or down. When that ecosystem gets thrown off (a state called dysbiosis), the immune dysfunction gets worse. It's a nasty feedback loop, and it's one of the reasons IBD is so stubborn to treat. Researchers recruited 48 people with IBD — a little over half with ulcerative colitis, the rest with Crohn's — and gave them vitamin D supplementation over an eight-week window. Then they used a technique called multi-omics analysis, which basically means looking at genes, proteins, and metabolic byproducts all at once, to see what changed. The results were more coordinated than you might expect from a single nutrient: What's compelling isn't any single change — it's that all four shifted in the same direction, at the same time. That points to something more systemic than a symptom bandage. Here's the interesting part. Vitamin D doesn't just do one thing to one place. In this study, it appeared to influence immune cells, gut bacteria, and metabolic pathways simultaneously, coordinating them in a way that suggests it's playing a regulatory role rather than a pharmacological one. On the immune side, it quiets Th17 activity while giving Tregs a boost. On the microbiome side, it seems to create conditions where beneficial bacteria can outcompete the troublemakers. And those beneficial bacteria, in turn, produce more short-chain fatty acids, which further stabilize the gut lining and reduce inflammation. It's a positive feedback loop instead of a vicious one — the immune system calms down, the microbiome balances out, and both effects reinforce each other. That kind of multi-system coordination is exactly what chronic conditions like IBD need. Most medications hit one target hard. A signaling nutrient like vitamin D nudges several targets at once, gently. Vitamin D deficiency is already widespread — some estimates put insufficient levels in roughly 40% of American adults. Among people with IBD, it's dramatically worse. Some research suggests up to 70% of IBD patients are running low. There are structural reasons for this: malabsorption during flares, reduced appetite, dietary restrictions, and less time outside when symptoms are bad. The overlap creates a chicken-and-egg situation. Low vitamin D may worsen IBD symptoms, and IBD symptoms tend to drive vitamin D lower. Breaking that cycle is worth trying, even if the science is still catching up. One important caveat, though — and this matters. Vitamin D is not a replacement for prescribed IBD treatment. The research frames it as a complementary tool that works alongside medications, not instead of them. Anyone selling you a supplement as a substitute for real medical care isn't reading the same studies. If any of this has you curious, here's the practical path forward: What I find genuinely interesting about this research isn't the vitamin D angle alone — it's what it reinforces about the gut. Increasingly, the science keeps pointing back to the digestive system as central to immune regulation, mood, energy, and inflammation across the entire body. The gut isn't just where food gets processed. It's where the body decides what's a threat and what isn't. That framing matters for anyone with a chronic inflammatory condition. It means the small daily choices — what you eat, how much sun you catch, whether your microbiome is fed with fiber and fermented foods, whether you're actually resting — add up in ways that show up in bloodwork and symptom flares. Nutrients like vitamin D are one piece of that, but they work best inside a bigger context of gut-supportive living. For readers looking to go deeper into gut health, immune balance, and the kinds of intentional healing environments where those pieces come together, a curated selection of relevant wellness and recovery retreats can be browsed on our marketplace here. Whatever you decide, start with the blood test. It's cheap, it's fast, and it tells you something real. From there, the conversation with your gastroenterologist gets a lot more productive — and the path forward, whatever it looks like, gets a little clearer.
Type 2 Diabetes and Diet: What Actually Moves the Needle on Longevity
A type 2 diabetes diagnosis has a way of rearranging your relationship with food overnight. Yesterday, a sandwich was a sandwich. Today it's a math problem. And somewhere between the pamphlets your doctor handed you and the panic-Google session that followed, you probably ran into a hundred different opinions about what a “diabetes-friendly” plate is supposed to look like. Here's the more useful truth, and the one that doesn't get said enough: you don't need to have eaten perfectly before your diagnosis to benefit from eating better now. A long-running analysis of nearly eight thousand people with newly diagnosed type 2 diabetes suggests that the shift itself — the improvement — is where a lot of the payoff lives. Not the starting line. The direction of travel. That's a quietly hopeful finding, and it's worth unpacking, because it changes how you might approach the next meal you cook. Diet quality has been studied to death in the context of preventing diabetes. What happens after someone develops the condition — how their eating shifts, and whether those shifts matter for how long they live — has gotten a lot less attention. This analysis went after that gap. The team followed 7,795 adults from two long-running cohorts (the Nurses' Health Study and the Health Professionals Follow-Up Study), all newly diagnosed with type 2 diabetes and free of heart disease or cancer at the time. Every four years, for up to 24 years, participants reported what they were eating. Researchers then scored those diets against 11 established healthy eating patterns — the DASH diet, the Planetary Health Diet, and others in that family. Two questions drove the analysis. First, did people who ate healthier after diagnosis live longer? Second, did people whose diets improved after diagnosis fare differently from those who didn't change much? The answers were subtly different, and the second one is where things get interesting. Over the follow-up period, 3,509 participants died — 1,079 from heart disease, 649 from cancer. When researchers crunched the numbers, both a high-quality post-diagnosis diet and a meaningful improvement in diet quality were linked to lower mortality. But the improvement effect was bigger. People with the healthiest post-diagnosis diets had an 8% to 22% lower risk of dying from any cause compared with those eating the worst. Fine. Expected. But people whose diets improved the most — regardless of where they started — had an 8% to 37% lower risk. Read that again. Someone who began with a mediocre diet and cleaned it up got a bigger relative benefit than someone who was already eating reasonably well and stayed the course. A quick honest caveat: this is observational research. It can show a link between changes and outcomes, but it can't prove the diet changes themselves caused people to live longer. People who improve their diets often improve other things too — sleep, movement, medical follow-through. Still, the association held across 11 different eating patterns, which is the kind of consistency that's hard to hand-wave away. Short answer: no. Longer answer: also no, but in a useful way. The 11 eating patterns the researchers evaluated weren't identical. DASH leans toward blood-pressure-friendly foods. The Planetary Health Diet emphasizes sustainability alongside nutrition. Others prioritize Mediterranean staples or plant-forward eating in different proportions. None of them clearly beat the others. Each was independently associated with better survival. What they shared, though, is worth noticing. Every one of those patterns tilts toward the same basic ingredients: vegetables, fruit, whole grains, legumes, nuts. And every one of them dials back the ultra-processed stuff, the refined carbs, the excess red and processed meat. If you squint, they're variations on a theme rather than competing philosophies. That's actually freeing. It means you're not locked into a single branded eating plan. You can build meals around real, whole, mostly-plant foods in a way that fits your culture, your budget, your household, and — this matters more than diet books admit — the things you'll actually eat on a Tuesday night when you're tired. If you're staring down a new diagnosis (or an old one you've been avoiding), the useful move isn't a total overhaul. It's a series of small, repeatable changes that nudge your usual meals in a better direction. A few that map onto the eating patterns in the study: Nothing on that list is revolutionary. That's kind of the point. The reason “diet advice” feels overwhelming is that it's been packaged and rebranded a thousand times, when the underlying signal has stayed remarkably steady for decades. Metabolic conditions like type 2 diabetes rarely exist in a vacuum. Food is part of it. So is stress, sleep, movement, and — for a lot of people — the relationship with food itself. Emotional eating, blood-sugar-spiking comfort routines, and the low-grade despair that a chronic diagnosis can bring: these are real, and they don't get solved with a meal-planning app. This is where broader healing work has quietly earned a place at the table. Some readers arrive at plant medicine or contemplative retreats because they're stuck in patterns — with food, with substances, with themselves — that willpower alone hasn't budged. Ayahuasca, psilocybin, and other master plants aren't a treatment for diabetes, and no serious facilitator would frame them that way. But they can loosen the psychological grip of the habits that make blood-sugar management harder: the compulsive eating, the numbing, the sense that nothing will ever change. If your diagnosis has surfaced questions bigger than what's on your plate — questions about how you got here, what you've been avoiding, what a healthier life would actually look like — those questions deserve room too. For readers who want to take that inquiry further, a range of curated plant-medicine and healing retreats can be browsed on our marketplace here. The dietary work is real work. The interior work often runs alongside it. For people with type 2 diabetes, improving diet quality after diagnosis was linked to a meaningfully lower risk of dying over the following two decades — and the improvement itself seemed to matter more than the specific plan. You don't need a perfect starting point. You don't need to pick the “right” named diet. You need to move, meaningfully, in the direction of more plants, more whole foods, less ultra-processed noise, and to keep going. The next meal is the one that counts. That's not inspirational fluff — it's what the data actually says.
When Ibogaine Doesn't Feel Like It Worked: What to Do Next
You flew across a border, paid thousands of dollars, sat through the medical screening, took the flood dose, endured the long grey dawn — and now you're home, and you feel exactly the same. Maybe worse. The forums promised a reset. Your facilitator talked about a window. And you're staring at the ceiling wondering if you got a dud batch of iboga or if you're just the person it doesn't work on. This is one of the least-discussed corners of the psychedelic and plant medicine conversation, and it deserves a straight answer. Ibogaine and its parent plant, iboga, have earned a real reputation in addiction recovery circles — especially for opioid dependence — but the story that gets told publicly is almost always the miracle version. The person who walked in hooked and walked out free. What happens to everyone else? Let's talk about it. Ibogaine is a psychoactive alkaloid extracted from the root bark of the Tabernanthe iboga shrub, used ceremonially by the Bwiti of Gabon for centuries and adopted by Western addiction clinics over the last few decades. Its biggest claim to fame is interrupting opioid withdrawal — a lot of people describe waking up after a flood dose with the physical craving simply gone. That is not the same as being healed. The medicine appears to do two things at once. It resets certain receptor systems (which is what blunts withdrawal), and it produces a long, often confronting waking-dream state in which people revisit memories, decisions, and behavioural patterns. The first effect is chemistry. The second effect is psychological work. If only the first one lands for you, you might feel physically lighter but emotionally untouched. That's not a failure — it's an incomplete arc. Master plants — a term that spans iboga, ayahuasca, San Pedro, and psilocybin mushrooms in different traditions — are teachers, not procedures. They open doors. Whether you walk through is a separate question, and the answer often unfolds over months, not hours. There are more reasons than most retreats will tell you. Some are boring. Some are important. All of them are worth ruling out before you conclude the medicine failed. Give it ninety days at minimum. That number isn't magic, but it's roughly the window in which most people who report benefit start noticing the shift. In the first two weeks you're usually just physically recovering — ibogaine is hard on the body, and the fatigue can mask everything else. Weeks three through six tend to be when subtle mood changes register. After that, the behavioural changes (or their absence) become visible. Track something concrete during this window. Not feelings — feelings lie. Track specific behaviours: how many times you reached for the substance, how often you snapped at your partner, how many mornings you got out of bed without dread, how long you could hold a difficult conversation before shutting down. If any of those needles are moving, the medicine did something, even if the sky didn't crack open. And be honest with yourself about what you were hoping for. A lot of people arrive at plant medicine looking for a rescue — one big experience that dissolves a lifetime of patterns. That does happen. It's just not the common outcome, and treating it as the benchmark sets you up to miss real progress. Here's the thing about psychedelic healing that the retreat brochures skip: the ceremony is maybe twenty percent of the work. The rest is integration — the slow, unsexy process of translating what happened (or didn't happen) into how you actually live. Most people who come home feeling nothing skipped or shortchanged this part, often because their retreat didn't offer real aftercare. Integration for ibogaine specifically means a few concrete things. Sleep gets weird for weeks — protect it. Cravings can return in waves rather than a single crash — have a plan for the waves. The insights that do land often feel obvious in retrospect, which makes them easy to dismiss; write them down anyway, in the exact language they arrived in. And find someone to talk to who understands the terrain. A therapist with psychedelic-informed training, an integration circle, or a peer who's been through it can be the difference between a medicine experience that fades and one that reshapes your life. If you did ibogaine for addiction recovery specifically, the post-treatment window is when the actual work of building a new life happens. The medicine can interrupt the physical dependency. It cannot pay your rent, choose your friends, or fill the hours you used to spend using. That part is on you, and it's the part where most relapses happen — not because ibogaine failed, but because the scaffolding around it was too thin. This is worth considering honestly. Ibogaine has a specific character — it tends to be diagnostic, showing you the mechanics of your patterns in a somewhat cold, procedural way. Some people need that. Others need the heart-opening quality of psilocybin, or the deep somatic release of ayahuasca, or the gentleness of a well-facilitated MDMA session. There's no universal plant medicine for addiction or trauma or depression, despite what any single retreat will tell you. If ibogaine left you cold, that's real information. It doesn't mean plant medicine isn't for you. It means this particular teacher wasn't the one, or wasn't the one right now. Some people find their way to ayahuasca a year later and everything ibogaine hinted at finally lands. Others do a psilocybin retreat and get the emotional catharsis they were unconsciously hoping ibogaine would provide. The exploration is legitimate — just be thoughtful about it and give yourself real time between journeys. Some clinics offer booster sessions, and there are people for whom a second ibogaine experience did what the first couldn't. There are also people who chased the miracle with repeated flood doses and got nowhere. If you're considering a second session, wait at least six months, work with a facilitator who will honestly assess whether more medicine is what you need (versus more integration work), and get updated cardiac clearance. Ibogaine is not a substance to stack casually. The uncomfortable truth is that plant medicine is a powerful tool, not a guarantee. It works spectacularly for some people, incrementally for many, and not at all for a few. Being in the second or third camp doesn't mean you're beyond help — it usually means the path is longer and more layered than one ceremony can hold. If you're weighing whether a different approach might land better for you, a curated range of ibogaine and plant medicine retreats can be browsed on our marketplace here. Take your time with the decision. The medicine will still be there when you're ready, and the version of you that shows up next time will be a different person than the one who showed up this time — which is often the point.
Big Pharma, Ibogaine Trials, and Medicaid: What the Psychedelic Industry Shift Means for Retreat-Seekers
Something strange is happening at the top of Google when you search for the word psychedelic. It's not a shaman. It's not a retreat center in Iquitos. It's a pharmaceutical ad. Specifically, more often than not lately, it's an ad for Spravato — Johnson & Johnson's esketamine nasal spray. For a movement that not long ago existed mostly in underground ceremonies and academic footnotes, this is a genuinely weird moment. If you're someone quietly researching whether an ayahuasca or psychedelic retreat might help you with depression, addiction, or a stuck patch of your life, the corporate side of this world can feel very far away from what you're actually looking for. But it isn't. What happens in boardrooms and clinical trials shapes what's legal, what's affordable, and eventually what shows up in your insurance paperwork. Below, I'll walk through what's actually going on right now in psychedelic drug development and policy — and, more importantly, what any of it means if you're weighing a retreat. Here's the short version: large drugmakers have noticed that people are typing words like psychedelic, ketamine therapy, and even specific compound codes like COMP360 and DT120 into Google. Those searches used to lead to hippie forums and retreat blogs. Now, increasingly, they lead to a landing page for Spravato, or an at-home ketamine service, or a competing antidepressant like Rexulti. Compass Pathways' COMP360 is a synthetic psilocybin candidate. Definium Therapeutics is running LSD trials for generalized anxiety disorder. When someone Googles those product names, they're already deep in the funnel — probably a patient, a caregiver, or a curious clinician. Bidding on those keywords is a smart, cold-blooded move by pharmaceutical marketers. It also tells you where they think the puck is going. The subtext for a retreat-seeker is worth spelling out. Big pharma is now treating the psychedelic space as a real market. That means more money flowing in, more legitimacy, and eventually more competition — but also more medicalization. Whether you find that reassuring or unsettling probably depends on why you're drawn to plant medicine in the first place. Ibogaine — the alkaloid from the West African iboga root — has spent decades as the whispered secret of opioid recovery. People with heroin or fentanyl addictions travel to Mexico, Costa Rica, or Portugal, undergo a grueling multi-hour experience, and often come back describing it as the thing that finally broke the loop. The catch: ibogaine can be cardiotoxic, and until recently, U.S. researchers had almost no institutional support to study it properly. That's changing. ARPA-H — the federal agency modeled on DARPA but focused on health — has opened a funding opportunity called ASCENT-IBO, aimed at bankrolling ibogaine trials. This isn't a small grant program. ARPA-H is the closest thing the U.S. has to a moonshot lab for medicine. When it puts its name on a compound, other funders and universities follow. There's also been movement around the University of Miami transferring an ibogaine Investigational New Drug application to the federal government, with the current administration publicly acknowledging it. Whatever your politics, the practical effect is that ibogaine is being pulled out of the shadows and into a real regulatory pathway. If you or someone you love has been researching ibogaine for addiction, this matters. It means clinical evidence — the kind that eventually persuades insurers and skeptical family members — is finally on the way. Here's a sentence I didn't expect to write this year: a serious policy report just outlined a path to Medicaid coverage of psychedelic therapies. The Center for Health Care Strategies (CHCS) laid out what it would take — provider credentialing, billing codes, treatment protocols, safety guardrails — for state Medicaid programs to reimburse psychedelic-assisted care. Medicaid coverage would be transformative for a very specific reason: right now, everything about legitimate psychedelic therapy is priced for the well-off. A single ketamine session at a legal clinic runs several hundred dollars. A ceremonial ayahuasca retreat in Peru, all in with flights, often lands between $2,500 and $6,000. Ibogaine treatment in a medically supervised setting can hit $10,000 or more. If you're working class, uninsured, or on public assistance — exactly the demographic most likely to be dealing with untreated addiction and trauma — those numbers may as well be theoretical. Insurance coverage would flip that. It would also, inevitably, change what "psychedelic therapy" looks like. Standardized dosing. Two-hour sessions instead of all-night ceremonies. No icaros, no shaman, no jungle. A clinical room somewhere in Cleveland. Whether that's progress or loss depends on what you were hoping to find. Zoom out. There are essentially three lanes forming for someone who wants access to psychedelics for healing: Each lane has its trade-offs. The medical lane will eventually be the cheapest and safest for the average person, but it's still years from truly opening up. The retreat lane is available now, offers the traditional container that many people intuitively want, but requires more due diligence from you. The gray lane can be a disaster or a lifeline, and you generally don't know which until later. If you're leaning toward a retreat rather than waiting years for the medical system to catch up, a few honest observations from watching this space closely: One thing that's easy to lose in the flurry of trial readouts and Medicaid reports: the plants themselves. Ayahuasca, iboga, San Pedro, and psilocybin mushrooms have been used in ceremonial contexts for centuries — in some cases millennia — under the guidance of people who understand them as teachers, not medications. Indigenous traditions call them master plants for a reason. Pharma will extract, isolate, and standardize. That's what pharma does. There's real value in it — a controlled dose in a controlled setting saves lives that the retreat model can't reach. But the ceremony holds something the clinic doesn't: a container built around meaning, community, song, and time. When you sit in a maloca at three in the morning and everything you've been avoiding for a decade rises up to be looked at, the setting matters. The people around you matter. The tradition matters. Neither approach is wrong. They're answering different questions. The medical model asks: how do we reduce symptoms of a diagnosed condition? The plant-medicine tradition asks: how do we help this person meet themselves? Both are useful. If you're deciding between them, start with which question is actually yours. A few things worth keeping an eye on if this whole space interests you: For readers who want to take this further, a curated range of ayahuasca, ibogaine, and psilocybin retreats can be browsed on our marketplace here. Whichever lane you eventually choose, the most useful thing you can do right now is slow down, ask specific questions, and trust your own read on the people who'd be holding space for you. The industry is changing quickly around this work. The work itself — meeting yourself honestly, with support — hasn't changed at all.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
MDMA Therapy vs. Ibogaine: Which Path Fits Your Healing?
People ask me this question more than almost any other: should I do MDMA-assisted therapy or an ibogaine retreat? And honestly, the fact that someone is even weighing the two tells me they're thinking about their healing seriously. These are not interchangeable experiences. They come from different worlds, work on different parts of the psyche, and ask different things of you before, during, and after. So let's actually break it down. Not as a sales pitch for either, but the way I'd talk it through with a friend who's stuck — someone battling addiction, trauma, or a depression that hasn't budged despite years of talk therapy and SSRIs. Both MDMA and ibogaine sit squarely inside the psychedelic and plant medicine conversation, but calling them by the same name is a bit like calling a violin and a chainsaw both “tools with strings.” MDMA is a synthetic compound, first patented over a century ago and best known in the clinical world for its remarkable effect on trauma. In a therapeutic setting — not a nightclub — it produces a state researchers call “fearless introspection.” The amygdala calms down. Oxytocin floods the system. People find they can talk about the worst things that ever happened to them without flinching or dissociating. Ibogaine is a different animal entirely. It's an alkaloid extracted from the root bark of the iboga shrub, used ceremonially for generations by the Bwiti people of Gabon. It doesn't feel loving or soft. It's often described as a “waking dream” or a life review — hours of vivid, sometimes uncomfortable inner cinema where your memories, choices, and patterns get shown back to you. It's also physically demanding: ibogaine slows the heart, requires medical screening, and typically lasts 24 to 36 hours from onset to the “gray day” afterward. Different mechanisms, different vibes, different applications. One opens the heart. The other reboots the operating system. Here's where the honest answer diverges from the internet's answer. Ibogaine has an almost mythic reputation in addiction recovery — particularly for opioid dependence. And that reputation is earned. There's a well-documented effect where ibogaine appears to interrupt withdrawal from opioids in a way no other substance does. People walk into a clinic in active withdrawal and, after the session, describe feeling like the physical craving simply lifted. Not gone forever, necessarily — but the window of clarity it opens is real, and for many it's the doorway out. MDMA's addiction story is more nuanced. It's not primarily an anti-addiction medicine. But because so much addiction is trauma wearing a costume, MDMA-assisted therapy can be transformative for people whose substance use is rooted in unprocessed pain — childhood abuse, combat experience, sexual violence, chronic self-hatred. If you drink to bury something, MDMA helps you look at the something. I'll try to describe them plainly, because a lot of the retreat marketing out there is honestly useless. An MDMA session runs about six to eight hours. You lie down, usually with eyeshades and music, and two trained therapists sit with you. It doesn't feel psychedelic in the visual sense — no fractals, no hallucinations. What you get instead is an unusual clarity and warmth. You can revisit a memory that normally makes you shut down, and this time you stay in the room with it. People cry. People laugh at things that used to only make them cry. The insight is often quiet and matter-of-fact: oh, that's why I do that. Ibogaine is not that. Ibogaine is intense. The onset is heavy — many people feel nauseous, cold, or physically pinned to the mat. The visions can be relentless. You may see people from your past, hear conversations you'd forgotten, watch scenes from your own life play out as if projected on a wall. There's often no therapist doing active work with you during the peak — it's you and the medicine, alone in your head, for a long time. The next day is the “gray day,” a hollowed-out but oddly peaceful window where a lot of the real insight consolidates. One person told me MDMA felt like being held by a wise older sister. Ibogaine, they said, felt like being interviewed by their own soul. Both descriptions ring true. This part matters, and any retreat worth its salt will lead with it. Ibogaine has real cardiac risks. It prolongs the QT interval — the electrical rhythm of the heart — which is why reputable clinics run an EKG, blood work, and a full medication review before dosing. If you have a heart condition, an electrolyte imbalance, or you're on certain psychiatric medications (SSRIs need a lengthy taper), ibogaine is not for you. People have died from ibogaine, almost always in unregulated settings without medical oversight. Never do ibogaine anywhere that doesn't have a physician on site and continuous cardiac monitoring. Full stop. MDMA is generally physically safer in a therapeutic dose, but it's not risk-free. It elevates blood pressure and body temperature. People with cardiovascular disease, uncontrolled hypertension, or a history of serotonin syndrome from other medications need to be careful. And MDMA can be emotionally destabilizing in the weeks after — the “Tuesday blues” are real, and without good integration support, that dip can hit hard. Here's the framework I actually use when people ask: You'll notice I haven't called MDMA a “master plant.” That's because it isn't — it's a lab-made compound. Ibogaine, on the other hand, comes from iboga, which the Bwiti consider a master teacher plant in the same category ayahuasqueros place ayahuasca. That distinction matters if the traditional, ceremonial dimension is important to you. Some seekers want the science; others want the lineage. There's no wrong answer, but knowing which you're drawn to will shape the kind of retreat you end up in. Plenty of people, over the years, end up working with multiple medicines. Ibogaine for the acute break. MDMA for the trauma underneath. Ayahuasca or psilocybin later, for the ongoing spiritual work. This isn't a menu you pick once — it's a longer relationship with your own healing. Neither medicine is magic. I've seen people do ibogaine, feel spectacular for two months, then relapse because they went home to the same apartment and the same friends and the same wound. I've seen people do MDMA therapy, have a beautiful session, and then avoid the harder integration work because the session itself felt so good. The medicine is a lever. It gives you leverage on something that felt immovable. But you still have to move it. Also: legal status matters. Ibogaine is not federally legal in the U.S., which is why most retreats operate in Mexico, Costa Rica, Portugal, or the Netherlands. MDMA-assisted therapy is still moving through the FDA approval process and is available primarily through clinical trials or expanded-access programs, though a handful of legal international clinics offer it too. Do your homework on the specific country and setting. If you've read this far, you're probably not looking for a hype video. You're looking for a real decision. Talk to people who've done both. Read trip reports with a skeptical eye — the good ones and the bad ones. Book a consultation call with any retreat you're considering, and if they won't get on the phone with you before taking your deposit, walk away. For readers who want to take this further, a range of vetted ibogaine and psychedelic-assisted retreats can be browsed on our marketplace here. Whichever medicine you end up choosing — or if you decide the timing isn't right yet — the fact that you're being this careful about the decision is already a good sign. The people who do best with these medicines are almost always the ones who took the question seriously in the first place.
Ibogaine for Complex PTSD: What to Know Before You Consider a Retreat
Every few weeks I get an email that reads roughly the same. Someone in their thirties or forties, exhausted from years of therapy that helped a little but not enough, asking whether ibogaine could finally shift the weight of complex PTSD. They've usually tried SSRIs. Some have tried ayahuasca. A few have tried ketamine clinics. And now they're looking at ibogaine — the West African root bark that keeps showing up in stories about addiction recovery and, increasingly, trauma healing. So let's talk about it honestly. Ibogaine is one of the more powerful psychedelics on the map, and the conversation around it has moved well beyond opioid detox. People with complex PTSD are showing up at clinics in Mexico, Costa Rica, and Portugal because conventional care hasn't touched their symptoms. Some come back changed. Some don't. And some really shouldn't have gone in the first place. Complex PTSD isn't just PTSD with extra steps. The clinical picture involves prolonged, repeated trauma — often starting in childhood — that shapes how a person relates to themselves, other people, and their own body. Emotional flashbacks, chronic shame, dissociation, difficulty trusting anyone, a nervous system that runs hot even when nothing is happening. It's a diagnosis that lives partly in the brain and partly in the tissue. Standard trauma therapy — EMDR, somatic experiencing, IFS, prolonged exposure — can help enormously. But many people plateau. The insights arrive, the timeline gets clearer, and yet the felt sense of danger stays put. That's the wall a lot of people hit before they start looking at plant medicine and psychedelics as a possible next door. Ibogaine is the primary alkaloid in the root bark of Tabernanthe iboga, a shrub native to Central Africa. It's been used ceremonially in the Bwiti tradition of Gabon for generations, largely as an initiatory medicine. In the West, it first got attention in the 1960s as a possible addiction interrupter, and that reputation has stuck — most iboga clinics still market primarily to people struggling with opioids, stimulants, or alcohol. What's newer is the growing use of ibogaine for trauma that isn't tied to substance use. A landmark 2024 Stanford study of special-operations veterans with traumatic brain injury and PTSD reported significant, durable improvements in symptoms after a single ibogaine session in Mexico. That study lit up the field. Suddenly complex PTSD, chronic depression, and treatment-resistant despair started getting mentioned alongside heroin withdrawal. Here's what makes ibogaine different from most other master plants. The experience is long — often 12 to 24 hours of active journey, followed by a lighter afterglow that can last days. Many people describe it as autobiographical: the medicine seems to walk you through your own life, sometimes chronologically, showing scenes you'd forgotten or reframing scenes you thought you'd fully processed. It's less about cosmic union and more about being made to look at yourself with unusual clarity. People imagine psychedelic experiences as swirling colors and unity consciousness. Ibogaine is not that. It's usually described as more austere. Lying still, eyes closed, in a dim room, hearing what many describe as a low buzzing or the sound of a struck wire. Movement is difficult and mostly discouraged — the ataxia is real and lasts many hours. Nausea is common. Some people vomit early in the session. Then the visions begin. For someone with complex PTSD, this is where it gets interesting and where it gets hard. The medicine tends to bring up material without asking permission. Childhood scenes. Family patterns you've been circling in therapy for a decade. Somatic memories the body has been holding onto without your consent. There is no bailing out mid-flight. The experience is what it is until it isn't. Facilitators I've spoken with describe the same recurring pattern: the medicine shows people the origin of a stuck pattern, then shows them living inside it, then — often — offers something like a proposal. A different way of holding it. Not a magic erase, but a shift in relationship to the material. Whether that shift sticks depends heavily on what happens after the ceremony ends. Ibogaine is the psychedelic with the most serious physical risk profile, and this cannot be soft-pedaled. It affects the heart's electrical rhythm — specifically the QT interval — and there have been deaths, most linked to underlying cardiac issues, undisclosed medications, or clinics operating without proper screening. Any reputable ibogaine provider will require: If a clinic waves off any of this or offers to work around a medication issue, walk away. Cost is not the metric that matters here. Well-run ibogaine programs run somewhere between $6,000 and $15,000 for a full stay, and the reason they cost that much is the medical infrastructure. Cheaper isn't a bargain; it's usually a corner cut. Beyond cardiac risk, there's the psychological weight of the experience itself. For someone with complex PTSD, opening this much material in a single session, in an unfamiliar country, far from a therapist who knows their history — that's a lot. Not every trauma survivor is a good candidate. Active dissociative disorders, unstable psychosis history, or ongoing suicidality are usually contraindications, and a serious clinic will tell you so. Say you've talked to your doctor, cleared the cardiac screening, and you still feel called toward this. How do you actually pick a place? A few things to look for, and a few red flags I'd take seriously. Two other things worth mentioning. First, ibogaine is legal in some countries (Mexico, Costa Rica, New Zealand for medical use, and a handful of others) and not in the United States, where it remains Schedule I. Second, the retreat itself is maybe a quarter of the total work. What happens in the six months after — therapy, community, sleep, movement, staying off the substances the medicine may have shaken loose — is where the change either takes root or fades. Honestly? For some people with complex PTSD who have exhausted other options and who clear the medical bar, ibogaine can be one of the more significant experiences of their life. I've spoken to people who describe a before-and-after that stuck years later. I've also spoken to people for whom it opened material they weren't ready to hold, and who spent a hard year putting themselves back together with a good therapist. Both stories are true. Neither is the whole picture. What I'd say is this: if you're drawn to ibogaine, take your time. Read the Stanford study. Talk to a trauma therapist who won't dismiss the idea but also won't cheerlead it. Get the cardiac workup regardless of what you decide, because you'll want that baseline anyway. And if you do move forward, treat the ceremony as the beginning of the work, not the end of it. For readers who want to explore this further, a range of vetted ibogaine and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, decide it slowly — this is one of those choices that rewards patience and punishes hurry.
Intentional Tanning and Skin Aging: What the Latest Research Reveals
There's a specific kind of afternoon most of us know by heart. Towel on the grass, phone flipped face-down, the UV index quietly climbing into the red. Nobody's forcing anyone to lie there. We choose it — because a tan still reads, at least visually, as health. That reflex hasn't gone away, even after two decades of dermatologists patiently explaining that it should. What's strange is that the same generation now obsessed with longevity, morning sunlight, cold plunges, and $90 serums is also the one still baking on purpose. A new analysis in JAMA Dermatology put a number on the contradiction, and it's higher than most people would guess. If you're weighing your own habits — or side-eyeing a friend's — the data is worth sitting with for a minute. Researchers pulled data from 31,615 adults in the 2024 National Health Interview Survey, a nationally representative sample. Participants were asked a simple, direct question: do you ever go outside specifically to get a tan? They were also asked about sunburns in the past year, plus the usual laundry list of demographic and lifestyle factors — age, alcohol use, physical activity, how easily their skin burns. Roughly 30% of American adults said yes, they intentionally tan outdoors. Women outpaced men — 35.6% versus 26.6% — but the real headline was the age breakdown. Among women aged 18 to 29, the figure climbed to 48.1%. That's nearly one in two young women deliberately seeking UV exposure to change the color of their skin. And the burn rates tracked exactly where you'd expect. Half of intentional tanners reported at least one sunburn in the previous year, compared with 28.3% of people who weren't chasing a tan. This isn't a gentle habit with an occasional consequence. It's a habit that comes with routine, measurable damage. A tan is not a glow. Biologically, it's a bruise with better PR. When UV radiation hits skin, it damages cells at the DNA level. Melanocytes respond by pumping out more melanin, which darkens the skin in an attempt to shield the layers underneath from further hits. The color you see is the body's alarm system, not a sign that anything good is happening. Sustained exposure drives what dermatologists call photoaging — the slow, cumulative breakdown of collagen and elastin, the two proteins that give skin its bounce and structure. Once those fibers are damaged, they don't neatly regrow. Instead you get the classic constellation: fine lines etched into places they didn't used to be, patchy pigmentation, rougher texture, a slackness around the jaw and neck. Most of what people spend their thirties and forties trying to reverse was set in motion by their twenties. There's also the cellular story underneath the cosmetic one. Chronic UV exposure contributes to oxidative stress and accumulating DNA damage, and it accelerates the buildup of senescent cells — sometimes nicknamed “zombie cells” because they've stopped dividing but refuse to clear out. They just sit there leaking inflammatory signals that mess with the tissue around them. It's a quiet form of internal weather, and the sun is one of its main drivers. Here's the part that should sting a little if you're spending real money on your skin. Retinoids, vitamin C, peptide serums, in-office lasers, microneedling — the entire toolkit of modern skincare exists to do one main job: repair and prevent the damage that UV causes. You are, in essence, paying to undo something you can simply not do in the first place. None of this means outdoor life is the enemy. Walks, ocean swims, patio dinners, gardening, reading in the park — go do all of it. The distinction the research draws is narrow and useful: enjoying the outdoors is a different behavior than deliberately seeking UV exposure to change the color of your skin. The first has a hundred documented benefits. The second is essentially free damage. People who take longevity seriously tend to obsess over the elegant, complicated stuff — cold exposure, fasting protocols, VO2 max, sleep architecture, plant medicines, contemplative practice. Those all have their place. But the boring interventions still outperform most of the exotic ones on a per-dollar, per-minute basis. Sunscreen is one of them. It's cheap. It's fast. It works. There's also something worth noticing in the psychology of the tanning habit itself. Wanting a tan is rarely just about the tan. It's usually a proxy for wanting to look rested, wanting to look like you've been somewhere, wanting to feel a little more at home in your body. Those are legitimate desires. They're just not desires that a burn is going to solve — and the version of your face that shows up in ten years will thank you for finding other routes. The gentler frame here isn't shame. If you've spent a decade lying out, you haven't ruined anything; skin is remarkably responsive to a change in course, especially in your twenties and thirties. Start protecting it today and the trajectory bends. Habits stack. So does the damage you don't accumulate. If you're in the demographic the study flagged — a young woman who still catches herself checking the UV index for peak strength rather than peak avoidance — this is worth an honest audit. Not a crisis, not a purge of your summer plans. Just a quiet swap. Base tan sessions come out. Daily SPF goes in. Hats and shade become part of how you dress for warm weather instead of an afterthought. For readers thinking about skin resilience as part of a larger picture — the slow work of aging well, healing what's already there, feeling more at ease in the body you'll be living in for another fifty years — a range of wellness and healing-focused retreats that touch on skin health, longevity practices, and integrative recovery can be browsed on our marketplace here. The tan will fade by October either way. What you do to your collagen this summer is what stays.
Does Walking Speed Really Matter for Longevity? What the Research Actually Says
Here's a question that's been quietly bugging me for years: does it actually matter if you walk fast, or is the whole point just to move? I've watched retreat guests obsess over their step counters between ceremonies, and I've watched other guests amble through the jungle at what can only be described as sloth-pace and finish the week looking radiant. Turns out the sloths might have been onto something. A study published in JAMA followed nearly 5,000 adults over roughly a decade to figure out whether total daily steps or walking intensity did more to predict how long people lived. The findings are worth chewing on, especially if you're the kind of person who feels guilty every time your walk turns into a wander. The team pulled data from 4,840 American adults aged 40 and older who took part in the National Health and Nutrition Examination Survey. Between 2003 and 2006, participants wore a step-tracking device clipped to their hip during waking hours, for up to seven days. The device logged both total daily steps and how quickly people moved during their most active stretches of the day. Nobody was told to walk more or walk faster. Researchers just watched what people did naturally and sorted them into groups based on their typical daily step counts — from under 4,000 steps a day up past 12,000. Then they followed the group for an average of 10.1 years and tracked mortality across that window. That's the setup. Observational, decade-long, real-world behavior. It's the kind of study that can't prove causation, but it can spot patterns that are hard to ignore. Participants averaged around 9,124 steps a day. Over the follow-up period, 1,165 people in the group died. When the researchers used 4,000 daily steps as their baseline for comparison, the numbers got interesting fast. People hitting 8,000 steps a day had roughly half the risk of dying from any cause compared to those at 4,000. Push it to 12,000 steps and the risk dropped further still. The pattern held for deaths from heart disease and cancer specifically, and it held across men and women, younger and older adults, and several racial and ethnic groups. That kind of consistency is rare in nutrition and lifestyle research — usually a finding will show up in one subgroup and vanish in another. So more steps, less dying. Fine. But what about speed? At first glance, pace looked like it mattered. People who moved faster during their most active periods had a lower death risk. It was the kind of finding that would normally end up as a headline: Brisk Walkers Live Longer. Then the researchers controlled for total daily steps — meaning they asked, essentially, whether pace still mattered once you accounted for how much someone walked overall. And the association vanished. Poof. Gone. What actually predicted longevity wasn't how fast you moved. It was how much you moved. This is a genuinely useful finding for anyone who's ever felt like their leisurely walk didn't count as "real" exercise. It did. It does. The accumulation is what your body is responding to, not the intensity of any single session. Not exactly. Brisk walking still raises your heart rate, still challenges your cardiovascular system, still delivers benefits that a slow stroll doesn't quite match. If you're training for something specific, or you're focused on heart health, pace has its place. But here's the thing — you don't need to turn every walk into a workout. You don't need to strap on trainers and pump your arms every time you leave the house. A step to the mailbox counts. A slow walk with a friend counts. Pacing around the kitchen while you're on hold with your bank counts. And the study doesn't argue that 12,000 steps should be everyone's target either. The relationship was continuous — more movement generally meant lower risk — but that doesn't mean 12,000 is the magic number. Adding movement to whatever your current baseline is seems to be more useful than chasing a specific figure your smartwatch decided was correct. You don't need a new fitness routine. You need to notice the pockets of your day where sitting has quietly won. This was an observational study. It found associations, not proof. People who walk more tend to have other habits that quietly support longevity — better sleep, more social contact, less chronic stress, fewer hours parked in a chair. Researchers can adjust for some of these things, but they can't adjust for all of them. It's possible that walking is partly a marker of a life that already has other things going for it. Still, the biological story lines up. Regular movement supports circulation, insulin sensitivity, mood, sleep, and about a dozen other things that quietly shape how the next decade of your life is going to go. The mechanism isn't mysterious. If you're reading this while researching plant-medicine work or a psychedelic retreat, there's a reason movement keeps coming up in preparation guidance. Ceremonies ask a lot of the body. Facilitators routinely tell participants to build daily walks into the weeks leading up to a retreat — not to get "in shape" in some athletic sense, but because a body that moves regularly tends to metabolize experience, both chemical and emotional, more smoothly. The same is true afterward, during integration. Long walks after a ceremony are one of the oldest and most useful integration tools going. You don't need to jog. You don't need to hit some app-approved step goal. You just need to accumulate honest, unglamorous movement across your days — the kind that doesn't feel like exercise but adds up anyway. If any of this has you thinking about the broader arc of getting your body and mind ready for deeper work, a range of plant-medicine and psychedelic retreats can be browsed on our marketplace here. And in the meantime — go for a walk. Take your time.
Staying on the Spot: A Meditation Practice for Building Real Resilience
There's a phrase I keep coming back to: mind the business that belongs to you. It sounds like something a grandmother would say while shelling peas on a porch. But sit with it for a minute and it becomes something else — a quiet instruction for staying inside your own life when everything around you is pulling you out of it. That pulling is the whole problem, isn't it? You wake up, check the phone before your feet hit the floor, and by 8 a.m. you've already loaned your attention to twenty strangers. By evening you can't remember what you actually thought about that day. Just what you reacted to. Meditation teachers have a name for the opposite of that scattering. They call it staying on the spot. Coming home to yourself. Returning, again and again, to the one place your attention actually belongs. Most of us think we're paying attention most of the time. We're not. We're time-sharing our nervous system with a hundred half-open browser tabs — the argument from last week, the email we haven't answered, the thing our sister said at Thanksgiving three years ago, the vague dread about Tuesday. The mind wanders. That's what minds do. The trouble isn't that it wanders; the trouble is we don't notice when it does, and we don't come back. Staying on the spot is a small, honest practice. You sit. You breathe. When you notice you've left, you come back. That's basically the whole thing. It sounds too simple to matter, which is exactly why most people underestimate it. The people who actually do it, day after day, tend to become noticeably harder to knock off center. They're not calmer because life got easier. They're calmer because they stopped abandoning themselves every time something loud happened. It isn't emptying your mind. Nobody empties their mind, and if a teacher tells you they do, they're either lying or they're a houseplant. It also isn't about achieving some special state. You're not chasing bliss. You're just learning to notice where your attention has drifted to, and gently escorting it back. Over and over. That's the whole reps-and-sets of it. Here's a version of the practice you can do in ten minutes, right now, wherever you're reading this. Read through it once, then try it. Or read a step, do the step, then read the next. Do that once a day for a couple of weeks and something shifts. Not dramatically at first. You just start catching yourself sooner — the moment before you snap at your partner, the moment before you doom-scroll for an hour, the moment before you say yes to something you don't want to do. Readers here often ask why we cover contemplative practices alongside plant medicine and psychedelic healing. The honest answer is that they're the same skill set at different volumes. A meditation practice teaches you to notice where your attention has gone and bring it back. A ceremony — ayahuasca, psilocybin, whatever the modality — puts that same capacity under much more intense conditions. If you've never practiced coming back to yourself in ordinary life, coming back to yourself in the middle of a difficult journey is going to be genuinely hard. Facilitators I trust almost always ask new participants whether they have some kind of daily practice. Not because you need to be a monk to sit in ceremony. Because the people who tolerate the hard passages best are the ones who've learned, in small ways, to stay with discomfort instead of fleeing it. Ten minutes on a cushion isn't preparation for a psychedelic experience, exactly. But it's rehearsal for the same muscle. There's a phrase for what happens when you notice you've been distracted. It's called meta-attention — paying attention to how you're paying attention. It sounds like jargon, but it's the entire game. The mind wanders; that's automatic. The noticing is not automatic. Meta-attention is what you're training, quietly, every time you catch yourself and return. Over months, it starts to show up outside of meditation too. You notice you're irritated before you say the thing. You notice you're bored before you reach for the phone. You notice you're sad instead of eating your way through the pantry. That's the resilience part. Not stoicism. Not never getting knocked over. Just noticing sooner, coming back sooner, minding the business that actually belongs to you. A few things I've watched help people actually keep this going, rather than abandoning it after week two: If this kind of contemplative foundation is something you want to explore in a more immersive setting — whether alongside plant medicine work or on its own — a range of retreats that weave meditation into their healing containers can be browsed on our marketplace here. Wherever you practice, though, the instruction stays the same: notice where you went, come home, thank yourself for showing up. That's the whole path, one breath at a time.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
